Dai-Chen W.

About Dai-Chen W.

Trained cancer biologist experienced in target therapy and immunotherapy research in industry, academia, and research hospital (small molecule, monoclonal antibody, bi-specific, checkpoint blockade, cytokine-fusion biologics)- Trained stem cell biologist researched hematopoietic cell differentiation, fate specification, and expansion (erythroid lineage focus), phenotypic characterization, functional characterization (in vivo, ex vivo), and cell therapy application (anemia)- 12 yrs post PhD, focusing on oncology therapeutics. Functions in the oncology biopharma industry include immuno-oncology biotherapeutics project lead, in vivo pharmacology (syngeneic, CDX, GEMM, humanized models), translational science (target engagement, biomarkers, indication & patient population prioritization), in vitro assay (immune cell functions, general cell-based assays, ADC cytotoxicity), MoA and IND-enabling studies- Works in biopharma industry contribute to IND filing (2019), journal publications (PNAS 2022, Nature Cancer 2020), and poster presentations (SITC 2019, SITC 2020)- Research projects in cancer biology (~15 yrs) address immune modulation (T, NK, myeloid), disease biology, tumor suppressor gene, signaling pathways, tumor microenvironment, epithelial versus stromal response, cancer stem cells, infection-related carcinogenesis, molecular genetics & genomics, reverse translational study (from clinical trials to preclinical re-discovery), as well as molecular, immunological, pathological association of diseases and pharmacodynamics- Proficient in designing and executing pre-clinical pharmacodynamic analysis and functional assays (in vitro, in vivo, ex vivo - murine and human tumors, tissues, immune populations and blood), GEMM development (involves multiple alleles that recapitulate human pathogenesis). Experienced in conducting or applying knowledge of broad biomarker platforms and databases (DNA level, transcript level, RNA in situ, immunohistochemistry, immunofluorescence, flow cytometry (12+), ELISA, Luminex, working with bioinformaticians)- Interfacing among cross-functional groups for operation, implementation, and timely deliverables; CRO management.

Experience

1. Senior Scientist Ii

   Exelixis

   Sep 2021 — Present